IntelliAM aiming for significant growth with £5 million Aquis IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKP.L Regulatory News (SKP)

  • There is currently no data for SKP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EPT Disclosure

23 Jan 2006 11:47

Credit Suisse Securities (Eur) Ltd23 January 2006 FORM 38.5 DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS (Rule 38.5 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION Name of exempt principal trader Credit Suisse Securities (Europe) Ltd Company dealt in Skyepharma Plc Class of relevant security to which the dealings Ordinary Sharesbeing disclosed relate (Note 1) Date of dealing 20 January 2006 2. DEALINGS (Note 2) (a) Purchases and sales Total number of securities Highest price paid (Note Lowest price paid (Note 3)purchased 3) (GBP) (GBP) 760,932 0.4400 0.4400 Total number of securities Highest price received Lowest price received (Notesold (Note 3) (GBP) 3) (GBP) 760,932 0.4400 0.4400 (b) Derivatives transactions (other than options) Product name, e.g. Long/short Number of securities Price per unit (Note 3)CFD (Note 4) (Note 5) (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Product Writing, Number of Exercise Type, e.g. Expiry Optionname,e.g. selling, securities price American, date money paid/call purchasing, to which (GBP) European receivedoption varying etc. the option etc. per unit relates (Note 3) (Note 5) (GBP) (ii) Exercising Product name, e.g. Number of Exercise price percall option securities unit (Note 3) 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the persondisclosing and any other person relating to the voting rights of any relevantsecurities under any option referred to on this form or relating to the votingrights or future acquisition or disposal of any relevant securities to which anyderivative referred to on this form is referenced. If none, this should bestated. ..................................................................... None ..................................................................... Date of disclosure 23 January 2006 Contact name Jenny Lundquist Telephone number 020 7883 4332 Name of offeree/offeror with which connected SkyePharma Plc Nature of connection (Note 6) Connected party Notes The Notes on Form 38.5 can be viewed on the Takeover Panel's website atwww.thetakeoverpanel.org.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
3rd Apr 201411:51 amRNSDirector/PDMR Shareholding
3rd Apr 201411:50 amRNSDirector/PDMR Shareholding
1st Apr 20144:58 pmRNSAnnual Financial Report
31st Mar 20147:45 amRNSProposed Placing and Open Offer to Raise £112m
31st Mar 20147:00 amRNSFinal Results
26th Mar 20147:00 amRNSNotice of Results
6th Mar 20142:44 pmRNSDirector Declaration
5th Mar 20147:00 amRNSBoard Changes
4th Mar 20149:47 amRNSHolding(s) in Company
3rd Mar 20143:38 pmRNSHolding(s) in Company
28th Feb 20147:02 amRNSBoard Change
21st Feb 20142:53 pmRNSAnoro Receives Positive Opinion from CHMP
10th Feb 20145:59 pmRNSHolding(s) in Company
10th Feb 20147:00 amRNSflutiform launched in France
4th Feb 20143:19 pmRNSHolding(s) in Company
31st Jan 20147:00 amRNSTrading Update
22nd Jan 20142:50 pmRNSPositive step towards flutiform approval in Spain
19th Dec 20137:45 amRNSANORO ELLIPTA RECEIVES REGULATORY APPROVAL IN US
18th Dec 20132:52 pmRNSUpdate on Lyon manufacturing facility
4th Dec 20137:00 amRNSCapital Markets meeting & flutiform sales update
25th Nov 20135:54 pmRNSDirector/PDMR Shareholding
25th Nov 201310:57 amRNSFurther re Directorate Change
19th Nov 20137:00 amRNSPartner Kyorin launches flutiform in Japan
11th Nov 201311:41 amRNSHolding(s) in Company
11th Nov 201310:42 amRNSDirector/PDMR Shareholding
30th Oct 201311:38 amRNSHolding(s) in Company
10th Oct 20137:00 amRNSInterim Management Statement
24th Sep 20133:39 pmRNSHolding(s) in Company
23rd Sep 20134:31 pmRNSHolding(s) in Company
23rd Sep 20139:31 amRNSHolding(s) in Company
20th Sep 20138:39 amRNSCapital Markets Day, Muttenz, Switzerland
20th Sep 20138:20 amRNSRELVAR ELLIPTA Receives Approval in Japan
20th Sep 20137:00 amRNSflutiform approved in Japan
19th Sep 20132:02 pmRNSHolding(s) in Company
19th Sep 20131:54 pmRNSHolding(s) in Company
19th Sep 20137:00 amRNSflutiform trial for COPD initiated in Europe
22nd Aug 201311:11 amRNSAppointment of Andrew Derodra as CFO
19th Aug 20134:02 pmRNSHolding(s) in Company
15th Aug 20135:20 pmRNSDirector/PDMR Shareholding
15th Aug 20137:00 amRNSHalf Yearly Report
14th Aug 20133:38 pmRNSHolding(s) in Company
1st Aug 20134:08 pmRNSHolding(s) in Company
31st Jul 20139:28 amRNSflutiform recommended for approval in Japan
8th Jul 20137:00 amRNSNotice of Results
20th Jun 201311:00 amRNSflutiform launch in Italy
19th Jun 201312:31 pmRNSHolding(s) in Company
10th Jun 201310:35 amRNSHolding(s) in Company
4th Jun 20134:40 pmRNSSecond Price Monitoring Extn
4th Jun 20134:35 pmRNSPrice Monitoring Extension
3rd Jun 20137:00 amRNSPresenting at Jefferies 2013 Healthcare Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.